Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on RVMD stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang has given his Buy rating due to a combination of factors that highlight the promising position of Revolution Medicines’ zoldonrasib in the competitive landscape of KRAS G12D inhibitors. The data from competitors, such as VSTM and GenFleet, indicate a strong objective response rate, but zoldonrasib’s performance remains competitive with a favorable safety profile compared to its peers.
Additionally, the ongoing trials for zoldonrasib in pancreatic ductal adenocarcinoma and non-small cell lung cancer have shown encouraging results, further supporting its potential in these indications. Despite the small patient numbers in competitor studies, which limit direct comparisons, the consistent treatment of patients with unconfirmed partial responses in zoldonrasib trials adds to its credibility. These factors collectively reinforce the positive outlook for Revolution Medicines’ stock, justifying the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $72.00 price target.